

**EFFECTIVE DATE:** 08|15|2017  
**POLICY LAST UPDATED:** 04|04|2017

## OVERVIEW

Corneal collagen cross-linking (CXL) is a photochemical procedure approved by the Food and Drug Administration for the treatment of progressive keratoconus and corneal ectasia.

## MEDICAL CRITERIA

### BlueCHiP for Medicare

Not applicable

### Commercial

Treatment of progressive keratoconus or corneal ectasia after refractive surgery in patients who have failed conservative treatment (eg spectacle correction, rigid contact lens) is covered with one or more of the indications listed below:

Progressive keratoconus or corneal ectasia is defined as 1 or more of the following:

- An increase of 1 D in the steepest keratometry value
- An increase of 1 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction
- A decrease  $\geq 0.1$  mm in the back optical zone radius in rigid contact lens wearers where other information was not available.

## PRIOR AUTHORIZATION

### BlueCHiP for Medicare

Not Applicable

### Commercial

Prior authorization is recommended for Commercial Products via the online tool for participating providers.

## POLICY STATEMENT

### BlueCHiP for Medicare

Corneal collagen cross-linking using riboflavin and ultraviolet A, is considered not medically necessary for all indications. The evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Note:** Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

### Commercial Products

Corneal collagen cross-linking using riboflavin and ultraviolet A may be considered medically necessary as a treatment of progressive keratoconus or corneal ectasia after refractive surgery in patients who have failed conservative treatment (eg spectacle correction, rigid contact lens)

Corneal collagen cross-linking using riboflavin and ultraviolet A is considered not medically necessary for all other indications as the evidence is insufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## **COVERAGE**

### **BlueCHIP for Medicare**

Benefits may vary between groups and contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for services not medically necessary.

### **Commercial Products**

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable surgery benefits/coverage.

## **BACKGROUND**

### **KERATOCONUS AND ECTASIA**

Keratoconus is a bilateral dystrophy characterized by progressive ectasia (paracentral steepening and stromal thinning) that impairs visual acuity. While frequently diagnosed at a young age, the progression of keratoconus is variable. Results from a longitudinal study with 7 years of follow-up showed that, over the study period, there was a decrease of 2 high- and 4 low-contrast letters in best-corrected visual acuity (BCVA).<sup>1,2</sup> About 1 in 5 patients showed a decrease of 10 or more letters in high-contrast visual acuity and one-third of patients showed a decrease of 10 or more letters in low-contrast visual acuity. Over 8 years of follow-up, there was a mean increase of 1.44 diopters (D) in First Definite Apical Clearance Lens (a rigid contact lens to measure corneal curvature) and 1.6 D in flatter keratometric reading. Ectasia (also known as keratectasia, iatrogenic keratoconus, or secondary keratoconus) is a serious longterm complication of laser in situ keratomileusis (LASIK) surgery and photorefractive keratectomy. It is similar to keratoconus, but occurs postoperatively and primarily affects older populations. It may result from unrecognized preoperative keratoconus or, less frequently, from the surgery itself. Similar to keratoconus, it is characterized by progressive thinning and steepening of the cornea, resulting in corneal optical irregularities and loss of visual acuity.

### **Treatment**

The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis (LASIK), although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments (see evidence review 9.03.14) is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (ie, corneal grafting) is the last line of treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors, but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs, and intracorneal ring segments. Frequently, a penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of disease and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking (CXL) has the potential to slow the progression of disease. It is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet A (UVA) irradiation. There are 2 protocols for CXL.

1. Epithelium-off CXL (also known as “epi-off”): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and UVA causes the formation of reactive oxygen species, leading to additional covalent bonds (crosslinking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-micron thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.

2. Epithelium-on CXL (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed. Currently, the only CXL treatment approved by the Food and Drug Administration (FDA) is the epithelium off method. There are no FDA-approved CXL treatments using the epithelium-on method. CXL is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. CXL may also have anti-edematous and antimicrobial properties.

## SUMMARY OF EVIDENCE

For individuals who have progressive keratoconus who receive collagen cross-linking (CXL) using riboflavin and ultraviolet A, the evidence includes multiple randomized controlled trials (RCTs), systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary end point (an intermediate outcome) of reducing maximum corneal curvature (Kmax) by 1 diopter (D) was achieved at month 3 and maintained at months 6 and 12 in CXL-treated patients, compared to sham controls. In the 2 RCTs, the difference in mean change in Kmax from baseline to 12 months was 1.9 and 2.3 D, respectively, favoring the CXL-treated patients. Long-term follow-up for visual acuity outcomes are needed. The adverse events associated with CXL include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but, in a few (1%-6%) patients, continued for 6 to 12 months. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have corneal ectasia after refractive surgery who receive CXL using riboflavin and ultraviolet A, the evidence includes multiple RCTs, systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. In both pivotal RCTs, the primary end point (an intermediate outcome) of reducing Kmax by 1 D was achieved at month 3 and maintained at months 6 and 12 in the CXL-treated patients compared to sham controls. In the 2 RCTs, the difference in mean change in Kmax from baseline to 12 months was 2.0 and 1.1 D, respectively, favoring CXL-treated patients. Long-term follow-up for visual acuity outcomes are needed. The adverse events associated with CXL include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month, but, in a few (1%-6%) patients, continued for 6 to 12 months. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## CODING

### BlueCHiP for Medicare

The following CPT code is not medically necessary:

**0402T** Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)

## Commercial Products

The following CPT code is medically necessary when the criteria above is met:

**0402T** Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)

## RELATED POLICIES

Preauthorization via Web-Based Tool for Procedures

Corneal Topography/Computer-Assisted Corneal Topography/Photokeratoscopy

Implantation of Intrastromal Corneal Ring Segments

## PUBLISHED

Provider Update, July 2017

## REFERENCES

1. Davis LJ, Schechtman KB, Wilson BS, et al. Longitudinal changes in visual acuity in keratoconus. *Invest Ophthalmol Vis Sci*. Feb 2006;47(2):489-500. PMID 16431941
2. McMahon TT, Edrington TB, Szczotka-Flynn L, et al. Longitudinal changes in corneal curvature in keratoconus. *Cornea*. Apr 2006;25(3):296-305. PMID 16633030
3. Avedro Inc. Photorexa® Viscous and Photorexa® Prescribing Label. [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/203324s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203324s000lbl.pdf). Accessed February 2, 2017.
4. Chunyu T, Xiujun P, Zhengjun F, et al. Corneal collagen cross-linking in keratoconus: a systematic review and meta-analysis. *Sci Rep*. 2014;4:5652. PMID 25007895
5. Papaioannou L, Miligkos M, Papathanassiou M. Corneal collagen cross-linking for infectious keratitis: a systematic review and meta-analysis. *Cornea*. Jan 2016;35(1):62-71. PMID 26509768
6. Hersh PS, Greenstein SA, Fry KL. Corneal collagen crosslinking for keratoconus and corneal ectasia: One-year results. *J Cataract Refract Surg*. Jan 2011;37(1):149-160. PMID 21183110
7. Inc A. Avedro Briefing Package for Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Device Panel of the Medical Devices Advisory Committee NDA 203324: Photrexa Viscous and Photrexa (riboflavin ophthalmic solution) and KXL System (UVA light source) Avedro, Inc. 2015; <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicaandOphthalmicDrugsAdvisoryCommittee/UCM435022.pdf>. Accessed February 7, 2017.
8. Center for Drug Evaluation and Research: FDA. Summary Review: Application Number 203324Orig2s000. [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2016/203324Orig2s000SumR.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig2s000SumR.pdf). Accessed February 2, 2017.
9. U.S. Food and Drug Administration. FDA Briefing Package for Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Device Panel of the Medical Devices Advisory Committee NDA 203324: Photrexa Viscous and Photrexa (riboflavin ophthalmic solution) and KXL System (UVA light source)Avedro, Inc. 2015; <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicaandOphthalmicDrugsAdvisoryCommittee/UCM435021.pdf>. Accessed February 7, 2017.
10. Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. *J Refract Surg*. Sep 2008;24(7):S720-725. PMID 18811118
11. Wittig-Silva C, Chan E, Islam FM, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology*. Apr 2014;121(4):812-821. PMID 24393351
12. Renesto Ada C, Barros Jde N, Campos M. Impression cytologic analysis after corneal collagen cross-linking using riboflavin and ultraviolet-A light in the treatment of keratoconus. *Cornea*. Oct 2010;29(10):1139-1144. PMID 20622670
13. Sykakis E, Karim R, Evans JR, et al. Corneal collagen cross-linking for treating keratoconus. *Cochrane Database Syst Rev*. 2015;3:CD010621. PMID 25803325

14. Meiri Z, Keren S, Rosenblatt A, et al. Efficacy of corneal collagen cross-linking for the treatment of keratoconus: a systematic review and meta-analysis. *Cornea*. Mar 2016;35(3):417-428. PMID 26751990
15. McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and metaanalysis. *Acta Ophthalmol*. Sep 28 2016. PMID 27678078
16. Padmanabhan P, Rachapalle Reddi S, Rajagopal R, et al. Corneal collagen cross-linking for keratoconus in pediatric patients-long-term results. *Cornea*. Dec 01 2016. PMID 27918352
17. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. *J Cataract Refract Surg*. May 2008;34(5):796-801. PMID 18471635
18. Raiskup F, Theuring A, Pillunat LE, et al. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. *J Cataract Refract Surg*. Jan 2015;41(1):41-46. PMID 25532633
19. Caporossi A, Mazzotta C, Baiocchi S, et al. Long-term results of riboflavin ultraviolet a corneal collagen crosslinking for keratoconus in Italy: the Siena Eye Cross Study. *Am J Ophthalmol*. Apr 2010;149(4):585-593. PMID 20138607
20. Caporossi A, Mazzotta C, Baiocchi S, et al. Riboflavin-UVA-induced corneal collagen cross-linking in pediatric patients. *Cornea*. Mar 2012;31(3):227-231. PMID 22420024
21. Asri D, Touboul D, Fournie P, et al. Corneal collagen crosslinking in progressive keratoconus: multicenter results from the French National Reference Center for Keratoconus. *J Cataract Refract Surg*. Dec 2011;37(12):2137-2143. PMID 22108109
22. National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013;

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

